Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCYC Bicycle Therapeutics	$8.70 +1.2%	$7.98	$6.10 ▼ $28.67	$595.58M	1.41	302,744 shs	306,844 shs
DNA Ginkgo Bioworks	$13.96 -6.3%	$9.38	$5.00 ▼ $16.85	$872.12M	1.48	2.01 million shs	1.54 million shs
EOLS Evolus	$9.53 -1.2%	$9.54	$8.67 ▼ $17.82	$622.19M	0.97	815,094 shs	1.48 million shs
IMRX Immuneering	$4.06 +1.5%	$2.87	$1.00 ▼ $4.69	$143.94M	0.38	912,264 shs	211,762 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCYC Bicycle Therapeutics	-1.26%	+6.97%	+17.65%	+2.14%	-63.51%
DNA Ginkgo Bioworks	+6.13%	+52.86%	+62.61%	+90.00%	+11.54%
EOLS Evolus	+0.73%	+3.32%	+0.31%	-17.17%	-21.54%
IMRX Immuneering	-2.44%	-6.98%	+36.05%	+175.86%	+247.83%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCYC Bicycle Therapeutics	3.8213 of 5 stars	4.4	2.0	0.0	2.9	4.2	0.6
DNA Ginkgo Bioworks	0.7282 of 5 stars	1.0	1.0	0.0	3.3	2.5	0.6
EOLS Evolus	3.7218 of 5 stars	3.5	0.0	3.5	1.6	3.3	0.6
IMRX Immuneering	3.1424 of 5 stars	3.3	2.0	0.0	2.2	5.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCYC Bicycle Therapeutics	2.70	Moderate Buy	$24.22	178.42% Upside
DNA Ginkgo Bioworks	2.00	Hold	$8.50	-39.09% Downside
EOLS Evolus	3.00	Buy	$23.75	149.21% Upside
IMRX Immuneering	2.60	Moderate Buy	$13.25	226.35% Upside

Current Analyst Ratings Breakdown

Latest IMRX, EOLS, DNA, and BCYC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/17/2025	BCYC Bicycle Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$32.00 ➝ $25.00
6/18/2025	IMRX Immuneering	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$8.00 ➝ $10.00
6/18/2025	IMRX Immuneering	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
6/18/2025	IMRX Immuneering	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
6/5/2025	IMRX Immuneering	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
5/8/2025	EOLS Evolus	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00 ➝ $22.00
5/7/2025	IMRX Immuneering	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$25.00 ➝ $21.00
5/6/2025	IMRX Immuneering	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00
5/5/2025	BCYC Bicycle Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$15.00 ➝ $17.00
5/2/2025	BCYC Bicycle Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$35.00 ➝ $32.00
5/2/2025	BCYC Bicycle Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$17.00 ➝ $14.00

(Data available from 7/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCYC Bicycle Therapeutics	$35.28M	17.08	N/A	N/A	$11.48 per share	0.76
DNA Ginkgo Bioworks	$227.04M	3.60	N/A	N/A	$13.17 per share	1.06
EOLS Evolus	$266.27M	2.31	N/A	N/A	$0.09 per share	105.89
IMRX Immuneering	$320K	456.62	N/A	N/A	$1.33 per share	3.05

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCYC Bicycle Therapeutics	-$169.03M	-$3.14	N/A	N/A	N/A	-790.07%	-25.54%	-21.23%	8/5/2025 (Estimated)
DNA Ginkgo Bioworks	-$547.03M	-$9.16	N/A	N/A	N/A	-198.84%	-52.35%	-27.14%	8/14/2025 (Estimated)
EOLS Evolus	-$50.42M	-$0.89	N/A	N/A	N/A	-20.40%	-759.04%	-20.14%	8/5/2025 (Confirmed)
IMRX Immuneering	-$61.04M	-$1.96	N/A	N/A	N/A	N/A	-119.22%	-99.22%	8/5/2025 (Estimated)

Latest IMRX, EOLS, DNA, and BCYC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	DNA Ginkgo Bioworks	-$1.44	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	BCYC Bicycle Therapeutics	-$0.95	N/A	N/A	N/A	$9.43 million	N/A
8/5/2025	Q2 2025	EOLS Evolus	-$0.09	N/A	N/A	N/A	$82.18 million	N/A
8/5/2025	Q2 2025	IMRX Immuneering	-$0.40	N/A	N/A	N/A	N/A	N/A
5/6/2025	Q1 2025	DNA Ginkgo Bioworks	-$1.23	-$1.58	-$0.35	-$1.68	$38.70 million	$48.32 million
5/5/2025	Q1 2025	IMRX Immuneering	-$0.41	-$0.42	-$0.01	-$0.42	N/A	N/A
5/1/2025	Q1 2025	BCYC Bicycle Therapeutics	-$0.86	-$0.88	-$0.02	-$0.88	$8.67 million	$9.98 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCYC Bicycle Therapeutics	N/A	N/A	N/A	N/A	N/A
DNA Ginkgo Bioworks	N/A	N/A	N/A	N/A	N/A
EOLS Evolus	N/A	N/A	N/A	N/A	N/A
IMRX Immuneering	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCYC Bicycle Therapeutics	N/A	14.86	14.86
DNA Ginkgo Bioworks	N/A	4.88	4.88
EOLS Evolus	22.00	2.34	2.16
IMRX Immuneering	N/A	7.48	7.48

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCYC Bicycle Therapeutics	86.15%
DNA Ginkgo Bioworks	78.63%
EOLS Evolus	90.69%
IMRX Immuneering	67.65%

Insider Ownership

Company	Insider Ownership
BCYC Bicycle Therapeutics	22.90%
DNA Ginkgo Bioworks	9.72%
EOLS Evolus	5.90%
IMRX Immuneering	22.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCYC Bicycle Therapeutics	240	69.25 million	53.40 million	Optionable
DNA Ginkgo Bioworks	640	58.53 million	52.84 million	Optionable
EOLS Evolus	170	64.48 million	60.67 million	Optionable
IMRX Immuneering	60	35.99 million	27.75 million	Not Optionable

IMRX, EOLS, DNA, and BCYC Headlines

Recent News About These Companies

Immuneering Corporation (NASDAQ:IMRX) Receives $13.25 Average PT from Brokerages

July 19, 2025 | americanbankingnews.com

Immuneering Corporation Rings the Closing Bell

July 16, 2025 | nasdaq.com

Immuneering Corporation (NASDAQ:IMRX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

July 16, 2025 | marketbeat.com

Immuneering Granted U.S. Composition of Matter Patent for Highly Differentiated Cancer Drug Candidate Atebimetinib

July 9, 2025 | globenewswire.com

Immuneering (IMRX) chief people officer Neufeld buys $2498 in stock

July 8, 2025 | investing.com

Insider Buying: Immuneering Corporation (NASDAQ:IMRX) Director Buys 3,000 Shares of Stock

July 8, 2025 | insidertrades.com

Immuneering Corporation (NASDAQ:IMRX) CEO Acquires $10,089.30 in Stock

July 4, 2025 | insidertrades.com

Immuneering Corporation (NASDAQ:IMRX) CEO Benjamin J. Zeskind Purchases 2,985 Shares

July 3, 2025 | marketbeat.com

Insider Buying: Immuneering Corporation (NASDAQ:IMRX) CEO Buys 7,015 Shares of Stock

July 3, 2025 | marketbeat.com

Immuneering Corporation (NASDAQ:IMRX) Director Thomas J. Schall Purchases 9,500 Shares

July 1, 2025 | insidertrades.com

Thomas J. Schall Purchases 9,500 Shares of Immuneering Corporation (NASDAQ:IMRX) Stock

June 30, 2025 | marketbeat.com

Immuneering Corporation (NASDAQ:IMRX) Insider Brett Matthew Hall Acquires 6,007 Shares

June 25, 2025 | insidertrades.com

Immuneering Corporation (NASDAQ:IMRX) CEO Benjamin J. Zeskind Acquires 21,000 Shares

June 21, 2025 | insidertrades.com

We're A Little Worried About Immuneering's (NASDAQ:IMRX) Cash Burn Rate

June 20, 2025 | finance.yahoo.com

Pre-Market Most Active for Jun 17, 2025 : IMRX, TSLL, VERV, RUN, SQQQ, TQQQ, KO, CRCL, DIS, QBTS, BBAI, NIO

June 19, 2025 | nasdaq.com

Insider Buying: Immuneering Corporation (NASDAQ:IMRX) Director Acquires 40,485 Shares of Stock

June 19, 2025 | insidertrades.com

Positive Phase IIa OS data on Immuneering’s novel MEK inhibitor

June 18, 2025 | thepharmaletter.comT

Immuneering Corporation to Host Conference Call for Phase 2a Clinical Trial Update on IMM-1-104 in Pancreatic Cancer

June 18, 2025 | nasdaq.com

Immuneering stock rises after positive pancreatic cancer trial data

June 17, 2025 | investing.com

Immuneering Shares Climb on Promising Pancreatic Cancer Trial Results

June 17, 2025 | msn.com

Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients

June 17, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMRX, EOLS, DNA, and BCYC Company Descriptions

Bicycle Therapeutics NASDAQ:BCYC

$8.70 +0.10 (+1.16%)

Closing price 04:00 PM Eastern

Extended Trading

$8.49 -0.21 (-2.41%)

As of 04:29 PM Eastern

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Ginkgo Bioworks NYSE:DNA

$13.96 -0.95 (-6.34%)

Closing price 03:59 PM Eastern

Extended Trading

$13.95 -0.01 (-0.04%)

As of 07:53 PM Eastern

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Evolus NASDAQ:EOLS

$9.53 -0.12 (-1.24%)

Closing price 04:00 PM Eastern

Extended Trading

$9.54 +0.01 (+0.10%)

As of 07:32 PM Eastern

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Immuneering NASDAQ:IMRX

$4.06 +0.06 (+1.50%)

Closing price 04:00 PM Eastern

Extended Trading

$4.01 -0.05 (-1.23%)

As of 07:50 PM Eastern

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time